Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Chief Business Officer | July 02, 2024 | July 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Stoke Therapeutics, Inc.
Report date July 02, 2024 · Filed July 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33 |
Reported balance
After 2024-07-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-07-02 · Sale · Disposed 2,467 · Balance 33 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2023. F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.83 to $13.74 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: The shares sold in the reported transactions include an aggregate 2,500 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d). |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-07-02 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-07-02 · Sale · Disposed 33 · Balance 0 F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported on this Form 4 were executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2023.
F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.83 to $13.74 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The shares sold in the reported transactions include an aggregate 2,500 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2020 Filed Jul 17, 2020 22:02 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,900 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-042943 · doc4.xml · derivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,011 Underlying: Common Stock · 1,900 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests 1/48th of the shares monthly,commencing one month from the date of grant, subject to reporting person's continued service through each vesting date. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 22:02 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,900 | $25.06 | $47,614.00 |
DisclosureSEC source: 0001209191-20-042943 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 22:02 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 1,900 | $2.19 | $4,161.00 |
DisclosureSEC source: 0001209191-20-042943 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2020 Filed Jul 9, 2020 21:41 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 913 | $22.41 | $20,456.86 |
DisclosureSEC source: 0001209191-20-042004 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.22 to $22.64 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes 913 shares of Common Stock acquired under the issuer's employee stock purchase plan on June 30, 2020. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 22:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,800 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-040613 · doc4.xml · derivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,911 Underlying: Common Stock · 3,800 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests 1/48th of the shares monthly,commencing one month from the date of grant, subject to reporting person's continued service through each vesting date. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 22:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 3,800 | $23.15 | $87,967.72 |
DisclosureSEC source: 0001209191-20-040613 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.88 to $23.80 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 22:08 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 3,800 | $2.19 | $8,322.00 |
DisclosureSEC source: 0001209191-20-040613 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:55 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,107 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-034091 · doc4.xml · derivative · entry 4 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,711 Underlying: Common Stock · 2,107 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests 1/48th of the shares monthly,commencing one month from the date of grant, subject to reporting person's continued service through each vesting date. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:55 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 500 | $27.48 | $13,742.00 |
DisclosureSEC source: 0001209191-20-034091 · doc4.xml · nonDerivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.40 to $27.55 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:55 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 1,607 | $27.08 | $43,521.26 |
DisclosureSEC source: 0001209191-20-034091 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.39 to $27.38 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2020 Filed Jun 3, 2020 20:55 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 2,107 | $2.19 | $4,614.33 |
DisclosureSEC source: 0001209191-20-034091 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 25, 2020 Filed Mar 26, 2020 22:01 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $20.25 | $0.00 |
DisclosureSEC source: 0001209191-20-021312 · doc4.xml · derivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-03-24 F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 25, 2020 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date. Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 00:25 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 42,779 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001209191-20-016360 · doc4.xml · derivative · entry 6 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,818 Underlying: Common Stock · 42,779 shares Expires 2018-12-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests 1/48th of the shares monthly,commencing one month from the date of grant, subject to reporting person's continued service through each vesting date. Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 00:25 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,324 | $0.00 Strike: $0.40 | $0.00 |
DisclosureSEC source: 0001209191-20-016360 · doc4.xml · derivative · entry 5 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,000 Underlying: Common Stock · 6,324 shares Expires 2026-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vests 1/4th of the shares on the date of grant, with an additional 1/48th (vesting monthly thereafter, subject to reporting person's continued service through each vesting date. Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 00:25 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 15,995 | $26.37 | $421,852.13 |
DisclosureSEC source: 0001209191-20-016360 · doc4.xml · nonDerivative · entry 4 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.14 to $26.61 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 00:25 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | SaleCommon Stock | 33,148 | $25.66 | $850,697.01 |
DisclosureSEC source: 0001209191-20-016360 · doc4.xml · nonDerivative · entry 3 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,995 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.13 to $26.12 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 00:25 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 42,779 | $2.19 | $93,686.01 |
DisclosureSEC source: 0001209191-20-016360 · doc4.xml · nonDerivative · entry 2 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 00:25 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | Exercise / conversionCommon Stock | 6,324 | $0.40 | $2,529.60 |
DisclosureSEC source: 0001209191-20-016360 · doc4.xml · nonDerivative · entry 1 Nash Huw M. · CIK 0001780085 · COO & CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,324 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.